CG Oncology (NASDAQ:CGON – Get Free Report) and Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership.
Insider and Institutional Ownership
26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 8.3% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares CG Oncology and Tarsus Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CG Oncology | $684,000.00 | 3,146.02 | -$48.61 million | N/A | N/A |
| Tarsus Pharmaceuticals | $129.62 million | 15.94 | -$135.89 million | ($3.81) | -14.18 |
Analyst Ratings
This is a summary of recent ratings and price targets for CG Oncology and Tarsus Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CG Oncology | 0 | 0 | 8 | 1 | 3.11 |
| Tarsus Pharmaceuticals | 0 | 1 | 4 | 1 | 3.00 |
CG Oncology currently has a consensus target price of $63.88, indicating a potential upside of 125.71%. Tarsus Pharmaceuticals has a consensus target price of $54.20, indicating a potential upside of 0.30%. Given CG Oncology’s stronger consensus rating and higher probable upside, equities research analysts plainly believe CG Oncology is more favorable than Tarsus Pharmaceuticals.
Profitability
This table compares CG Oncology and Tarsus Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CG Oncology | -10,642.98% | -18.97% | -15.36% |
| Tarsus Pharmaceuticals | -103.64% | -55.86% | -39.28% |
Summary
CG Oncology beats Tarsus Pharmaceuticals on 7 of the 11 factors compared between the two stocks.
About CG Oncology
CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
